Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 155,385	$ 183,259
Prepaid expenses and other current assets	5,127	3,267
Total current assets	160,512	186,526
Property, plant and equipment, net	1,207	650
Operating lease right-of-use assets	2,287	1,914
Restricted cash	505	160
Other long-term assets	299	181
Total assets	164,810	189,431
Current liabilities:
Accounts payable (including related party amounts of $35 and $1,343 respectively)	9,997	5,150
Accrued clinical trial expenses		1,402
Accrued expenses (including related party amountsof $2,499 and $2,330, respectively)	14,678	11,405
Accrued interest	854	477
Operating lease liabilities, current	708	487
Total current liabilities	26,237	18,921
Long-term debt, net of discount	95,264	89,671
Revenue interest financing liability	109,525
Operating lease liabilities	1,098	1,183
Other long-term liabilities	7,500	7,500
Total liabilities	239,624	117,275
Commitments and contingencies (Note 4)
Stockholders’ equity:
Preferred stock, $0.0001 par value; authorized shares - 40,000,000 at December 31, 2022 and 2021; no shares issued and outstanding at December 31, 2022 and 2021
Common stock, $0.0001 par value; authorized shares - 400,000,000 at December 31, 2022 and 2021; issued shares - 41,723,308 and 31,656,035 at December 31, 2022 and 2021, respectively; outstanding shares - 41,468,871 and 30,511,226 at December 31, 2022 and 2021, respectively	3	3
Treasury stock - 19 and 1 shares at December 31, 2022 and 2021, respectively
Additional paid-in capital	652,276	601,523
Accumulated deficit	(727,093)	(529,370)
Total stockholders' (deficit) equity	(74,814)	72,156
Total liabilities and stockholders’ equity	$ 164,810	$ 189,431